Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 74

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 74
---
.

(b) Warrants.

On September 4, 2024, we issued 579,711 pre-funded
warrants, 579,711 Series A Warrants and 579,711 Series B Warrants to investors in a private offering. The Pre-Funded Warrants are exercisable
immediately upon issuance and expire when exercised in full at an exercise price of $0.005 per share. The Series A Warrants and Series
B Warrants have an exercise price of $6.90 per share and will be exercisable beginning on the effective date of stockholder approval of
the issuance of the shares of Common Stock (the “Stockholder Approval”) upon exercise of the Common Warrants. The Series A
Warrants will expire five years from Stockholder Approval and the Series B Warrants will expire eighteen (18) months from Stockholder
Approval. H.C. Wainwright & Co., LLC acted as the exclusive placement agent in connection with the Private Placement. In
connection with the Private Placement, we issued to Wainwright the Placement Agent Warrants to purchase 43,479 shares of Common. The Placement
Agent Warrants have an exercise price equal to $8.625 per share and are exercisable beginning on the effective date of the Stockholder
Approval for five years from Stockholder Approval.

In January 2025, we issued warrants to purchase
up to an aggregate of 81,725 shares of common stock at an exercise price of $19.275 per share. The January 2025 Common Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance. We issued to the Placement Agent (or its designees) warrants to
purchase up to 3,065 shares of common stock. The January 2025 Placement Agent Warrants have an exercise price equal to $31.91 per share
and are exercisable upon issuance, or January 30, 2025, for twenty-four months from the date of issuance, or January 30, 2027.

On February 5, 2025, we issued warrants to purchase
up to an aggregate of 60,140 shares of common stock at an exercise price of $14.75 per share. The February 2025 Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance. We issued to the Placement Agent (or its designees) warrants to
purchase up to 4,511 shares of common stock. The February 2025